Fox Foundation Taps Finance and AI Titans to Speed Parkinson's Cure

NEW YORK, NY – February 27, 2026 – The Michael J. Fox Foundation for Parkinson's Research (MJFF) has fortified its leadership with the appointment of two industry titans, signaling a strategic intensification of its mission. Richard Fitzgerald, a private equity magnate, and Samir Kaul, a top-tier venture capitalist with a focus on artificial intelligence, have joined the foundation's Board of Directors. While their professional pedigrees are impressive, it is their deep, personal connections to Parkinson's disease that truly define this moment, embodying the foundation's ethos of pairing world-class expertise with a relentless, personal drive to find a cure.

The appointments are more than a routine shuffle; they represent a calculated fusion of high finance, cutting-edge technology, and the powerful human element that has propelled the MJFF since its inception. By bringing leaders from the worlds of private equity and AI-focused venture capital into its inner circle, the world's largest nonprofit funder of Parkinson's research is making a clear statement about its future strategy: leveraging every tool of modern capital and technology in the urgent battle against the neurodegenerative disease.

A Fusion of Personal Mission and Professional Power

Both new members bring a formidable combination of professional achievement and profound personal motivation to the 50-member board. Richard Fitzgerald is the Co-Founder and Managing Partner of CapitalSpring, a Nashville-based investment firm that has deployed over $3.9 billion in capital. His connection to the cause is immediate and deeply felt: his father, Dick Fitzgerald, has been living with Parkinson's since 2007. This personal stake has fueled a long-standing commitment to the foundation. Prior to his board appointment, Fitzgerald served for a decade on MJFF's Leadership Council and has been a driving force behind its Nashville fundraising efforts, co-chairing the successful “A Country Thing Happened on the Way to Cure Parkinson's” gala since its inception in 2023.

Samir Kaul's involvement is born from a similar place of personal experience, following the passing of his father, Pradman Kaul, with Parkinson's in 2025. As a Founding Partner and Managing Director at the influential Silicon Valley firm Khosla Ventures, Kaul's professional life is dedicated to identifying and funding transformative technologies in AI, health, and sustainability. His firm is known for taking calculated risks on disruptive innovations, a mindset that aligns perfectly with the foundation's aggressive research goals. With a scientific background that includes work on the Arabidopsis Genome Initiative, Kaul possesses a rare ability to bridge the gap between complex science and high-impact investment, a skill set now dedicated to accelerating progress for the millions of families affected by Parkinson's.

Venture Philanthropy in Action

The appointments of Fitzgerald and Kaul are a powerful illustration of a growing trend in medical research: venture philanthropy. This model moves beyond traditional grant-giving to adopt the strategic, results-driven mindset of the investment world. It's a philosophy that has been baked into MJFF's DNA since its founding. CEO and Co-Founder Debi Brooks, who herself came from the world of high finance at Goldman Sachs, has long championed a strategy of using philanthropic capital to "de-risk" promising but early-stage research, thereby attracting larger investments from the biopharma industry.

"Our community is at the heart of driving the Foundation's mission forward, and we are grateful to our Board of Directors for their steadfast support," said Brooks in a statement. "We are proud to welcome Richard and Samir to the Board. Each of them brings sharp business acumen and a shared passion for boldness in our work — I look forward to what we will accomplish together to end Parkinson's."

This "boldness" is now supercharged. Fitzgerald's expertise in strategic capital and scaling organizations is invaluable for managing the foundation's massive, multi-billion-dollar research portfolio. Kaul's venture capital perspective, honed by identifying the next world-changing technologies, brings an entirely new dimension to evaluating and funding novel research pathways.

The Next Frontier: AI and Advanced Finance in Research

The true impact of these appointments may be felt most acutely in the foundation's push toward the next frontier of medical discovery. Samir Kaul's presence is particularly timely. His firm, Khosla Ventures, is a major proponent and investor in the application of artificial intelligence across healthcare, from improving diagnostics to accelerating drug discovery. This aligns perfectly with MJFF's most ambitious undertakings.

The foundation's landmark Parkinson's Progression Markers Initiative (PPMI) has created the world's most robust open-access dataset for PD research. The sheer scale and complexity of this data—encompassing genetics, imaging, and clinical information—is an ideal challenge for advanced AI and machine learning algorithms. Kaul's expertise can help guide the foundation in leveraging these tools to uncover new patterns, identify novel biomarkers, and speed the validation of treatments. The 2023 breakthrough validation of a biological test for Parkinson's, the alpha-synuclein seed amplification assay (αSyn-SAA), is precisely the kind of discovery that AI can help translate into widespread clinical use more rapidly.

Simultaneously, Fitzgerald's financial acumen provides the strategic framework to fund these ambitious technological pursuits. As MJFF launches initiatives like "Targets to Therapies," which aims to bridge the gap between basic science and drug development, the ability to structure funding, build partnerships, and ensure financial efficiency is paramount. His experience in providing flexible, strategic capital to growing enterprises offers a direct parallel to the foundation's role in nurturing promising research from the lab to the clinic.

A Board Built on Shared Experience

While the business and tech acumen of the new members is a headline story, it is their shared experience that anchors their purpose. They join a board where over 80 percent of members have a close personal connection to Parkinson's disease. This is not a detached, theoretical exercise; it is a deeply personal fight being waged in the boardroom as well as the laboratory.

This unique governance model ensures that the foundation's strategic decisions are always grounded in the urgent reality faced by patients and their families. The appointments of Richard Fitzgerald and Samir Kaul are the ultimate expression of this model: they are not just bringing their professional toolkits, but the full weight of their personal histories. For the global Parkinson's community, this powerful combination of financial muscle, technological foresight, and unwavering personal commitment represents a formidable and hopeful new chapter in the quest for a cure.